Clinical trials: active, in Mali
Dysphagia, Eosinophilic Esophagitis
The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States
Background: Eosinophilic esophagitis (EoE) is a disease that causes inflammation in the esophagus. The esophagus is the tube that moves food from the mouth to the stomach.
- Trial name
- NCT07027826
- Testing
- Esophageal string test
- Where
- 3 sites in United States, Mali
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Motor Neuron Disease, Muscular Disease
Study of Inherited Neurological Disorders
This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development.
- Conditions
- Motor Neuron Disease, Muscular Disease, Muscular Dystrophy, Peripheral Nervous System Disease
- Trial name
- NCT00004568
- Where
- 2 sites in United States, Mali
- Volunteers
- 3,500 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Malaria
Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali
Malaria caused by Plasmodium falciparum continues to be a global problem with devastating consequences. A greater understanding of the immunologic and parasitologic factors associated with infection and disease is badly needed…
- Trial name
- NCT01168271
- Where
- 2 sites in Mali
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Background: Malaria is a disease that affects many people in African countries. It is caused by germs that are spread by mosquito bites. It can be fatal if not diagnosed and treated right away.
- Trial name
- NCT02471378
- Where
- Mali
- Volunteers
- 7,476 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy…
- Trial name
- NCT07758985
- Testing
- Cohort 1 low dose lotilaner with a high-fat meal, Cohort 2 high dose lotilaner in fasted state, Cohort 3 high dose lotilaner with a high-fat meal
- Where
- Mali
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
BPH Global Registry
Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options.
- Trial name
- NCT05543200
- Where
- 30 sites in United States, Canada and 19 more
- Volunteers
- 7,500 people
- Sponsor
- Société Internationale d'Urologie
Stillbirths and Infant Mortality
Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali
The double blind randomized controlled trial will assess the efficacy of oral azithromycin administered to pregnant women and/or infants during routine care in preventing stillbirths and mortality through 6-12 months of age in…
- Trial name
- SANTE (NCT03909737)
- Testing
- Azithromycin to pregnant women, Azithromycin to infants, No intervention to pregnant women
- Where
- Mali
- Volunteers
- 99,700 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Malaria (Plasmodium Falciparum)
PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in Mali
A randomized double blind, placebo-controlled study to assess the safety, tolerability, immunogenicity, and protective efficacy of 1, 6, 29-day PfSPZ-LARC2 Vaccine regimen given at a dose of 2 x10^5 PfSPZ or placebo in healthy…
- Trial name
- NCT07675785
- Testing
- PfSPZ-LARC2 Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Prevention of Malaria Transmission and Clinical Malaria
Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults
This is a Phase 2, randomized, double-blind, controlled study designed to evaluate the safety, tolerability, immunogenicity, vaccine efficacy, and functional activity of Pfs230D1-CRM197 conjugate vaccine with R21 nanoparticle…
- Trial name
- NCT07147400
- Testing
- 10µg of R21 with 50µg Matrix-M1, 6µg of Pfs230D1-CRM197 + 10µg of R21 with 50µg Matrix-M1 single vial coformulation, RABIVAX-S
- Where
- Mali
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Trivalent Salmonella Conjugate Vaccine (TSCV)
Trivalent Salmonella Conjugate Vaccine (TSCV)
This is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV).
- Trial name
- NCT05784701
- Testing
- TSCV (Full-strength), TSCV (Half-strength), Typbar-TCV
- Where
- Mali
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Meningoccocal Disease
Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
- Trial name
- PERS-ACYWX-03 (NCT07379151)
- Where
- 2 sites in Mali, The Gambia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Atopic Disease
Microbiome and Atopy in Mali
This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes.
- Trial name
- NCT07051902
- Where
- 2 sites in Mali
- Volunteers
- 288 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Pregnancy Related
Pregnancy Registry in Mali
This registry will assess pregnancy outcomes through demographic surveillance and prospective data collection at a health facility in Kalifabougou, Mali.
- Trial name
- NCT06468319
- Where
- Mali
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Nephroblastoma
Therapeutic Recommendations for Nephroblastoma
The study is based on results form 2 previous studies carried out by the GFAOP. The aim of this study is to evaluate the capacity of units to follow the recommendations in the protocol.
- Trial name
- GFANEPHRO20 (NCT04423484)
- Testing
- Data collection
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Burkitt Lymphoma
Recommendations for the Treatment of Children With Burkitt's Lymphoma
This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units…
- Trial name
- GFALMB2019 (NCT04425421)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 1,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Retinoblastoma
Therapeutic Recommendations For The Treatment Of Children With A Retinoblastoma
As the survival of children with retinoblastoma in high income countries is higher than 95% including the bilateral forms this study hopes to improve the outcome in low income countries in Africa by improving early diagnosis and…
- Trial name
- GFARB12019 (NCT04425434)
- Testing
- OBSERVATIONAL
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 4 more
- Volunteers
- 3,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Healthy Women of Child Bearing Potential
Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali
This will be a double-blind, individually randomised trial, to assess the safety, tolerability, immunogenicity, and protective efficacy of two and three doses of the R21/Matrix-M1 malaria vaccine or placebo given at 4 week…
- Trial name
- NCT06080243
- Testing
- R21/Matrix-M1, Saline and R21/Matrix-M1, Sterile isotonic (0.9%) normal saline
- Where
- Mali
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Pregnancy, Malaria, Antepartum
Safety of Antimalarials in the FIRst trimEster
The SAFIRE study aims to find effective treatments with acceptable safety for malaria in early pregnancy, a particularly sensitive time for the adverse consequences of malaria in pregnancy for both mother and baby.
- Conditions
- Malaria, Pregnancy, Malaria, Antepartum, Malaria (Uncomplicated)
- Trial name
- SAFIRE (NCT06962319)
- Testing
- dihydroartemisinin-piperaquine (DP), Pyronaridine-artesunate (PA), Artemether-lumefantrine
- Where
- 3 sites in Burkina Faso, Kenya and 1 more
- Volunteers
- 1,510 people
- Sponsor
- Liverpool School of Tropical Medicine
Pediatric Cancer
Hospital Based Registry of Childhood Cancer in Pediatric Oncology Units in French Speaking Africa
The ultimate aim of this registry is to collect precise information concerning the children coming to oncology units working with the French African Oncology Group.
- Trial name
- RFAOP (NCT03803735)
- Where
- 14 sites in Burkina Faso, Cameroon and 10 more
- Volunteers
- 10,000 people
- Sponsor
- French Africa Pediatric Oncology Group
Malaria Vaccine
Integrating Malaria Vaccine With Seasonal Malaria Chemoprevention in West Africa
This is a multi-site, multi-disciplinary, Phase-4 two-arm cluster-randomised non-inferiority trial in Burkina Faso and Mali to evaluate the effectiveness and real-life impact of a novel integrated delivery strategy of the R21…
- Trial name
- IMVACS (NCT06860178)
- Testing
- Annual campaign of the 3-dose primary series vaccine R21/Matrix-M aligned with SMC distribution in children aged 3-59 months
- Where
- 2 sites in Burkina Faso, Mali
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Epicentre